Anna Merlo

Publications36
h-index16
Citations1,050
Highly Influential Citations37
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Heslop
  • 789 Publications • 37,795 Citations
  • C. Rooney
  • 582 Publications • 37,042 Citations
  • A. Rosato
  • 527 Publications • 17,594 Citations
  • M. Brenner
  • 847 Publications • 45,664 Citations
  • Publications
  • Influence
MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
TLDR
Germline mutations in MAX are responsible for 1.12% of PCC/PGL in patients without evidence of other known mutations and should be considered in the genetic work-up of these patients.
Regulation of DNA Repair pathway choice in S/G2 by the NHEJ inhibitor CYREN
TLDR
It is proposed that CYREN is a direct cell-cycle-dependent inhibitor of cNHEJ that promotes error-free repair by homologous recombination during cell cycle phases when sister chromatids are present.
The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders
TLDR
Data collected confirm the clinical relevance of the use of EBV-specific cytotoxic T lymphocytes in the field of adoptive immunotherapy and suggest the increasing importance of this approach also against other tumors, concurrent with the increasing knowledge of the intimate and continuous interplay between the virus and the host immune system.
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
TLDR
Upon in vivo transfer in tumor-bearing mice, CAR-transduced T cells were capable to completely eradicate a disseminated neoplasia in the majority of treated animals, thus supporting the translation of such approach in the clinical setting.
Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders
TLDR
The complex interactions between EBV and innate immunity are reviewed and the therapeutic strategies involving both adaptive and innate immune system are summarized, in the light of a fruitful integration between these immunotherapeutic modalities for a better control of EBV-driven tumors.
Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors
TLDR
Comparing the therapeutic efficacy of EBV-specific CD4+ and CD8+ T cell lines upon adoptive transfer and immunohistochemical analysis indicates that HLA-II expression is fully retained in human PTLD samples, pave the way to use cultures of pure CD4- T cells in immunotherapeutic approaches for EBv-related malignancies.
Differential expression of constitutive and inducible proteasome subunits in human monocyte‐derived DC differentiated in the presence of IFN‐α or IL‐4
TLDR
The different proteasome profiles ofIFNDC and IL‐4DC were associated with a greater ability of IFNDC to present an immunodominant epitope that requires LMP7 expression for its processing, showing the impact of cytokines on APM component expression and hence the Ag‐processing ability of DC.
Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells
TLDR
This review aims at summarizing currently available data about functional and therapeutic relevance of cytotoxic CD4+ T cells in the context of viral infections and virus-driven tumors.
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
TLDR
The results indicate that lentiviral vectors represent a valid tool for stable and high-intensity expression of transgenic TCR and support clinical exploitation of this approach for therapeutic application.
Role of CD4+ Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer
TLDR
This review summarizes available data supporting the functional and therapeutic relevance of cytotoxic CD4+ T cells, with a particular focus on Epstein-Barr virus (EBV)-related disorders.
...
1
2
3
4
...